Journal of pharmacy practice最新文献

Assessment of Midodrine Initiation and Vasopressor Liberation in Patients With Septic Shock in a Community-Teaching Hospital. 某社区教学医院感染性休克患者Midodrine起始和血管加压素释放的评估。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-04 DOI: 10.1177/08971900251384131

Joel Kennedy, Alyssa Osmonson, Jessica A Starr, Sarah B Blackwell

{"title":"Assessment of Midodrine Initiation and Vasopressor Liberation in Patients With Septic Shock in a Community-Teaching Hospital.","authors":"Joel Kennedy, Alyssa Osmonson, Jessica A Starr, Sarah B Blackwell","doi":"10.1177/08971900251384131","DOIUrl":"https://doi.org/10.1177/08971900251384131","url":null,"abstract":"Purpose: In observational trials, midodrine decreased vasopressor duration, length of stay (LOS), and mortality but not in randomized controlled trials. The goal of this study is to assess the efficacy and safety of using midodrine to wean intravenous (IV) vasopressors in patients with septic shock. Materials and Methods: This single-center, retrospective study was conducted at a 505-bed community teaching hospital between September 2021 and December 2022. Patients were ≥18 years of age with septic shock, admitted to the intensive care unit (ICU), required IV vasopressors for hemodynamic support, and demonstrated clinical stability. Outcomes were compared across patients receiving IV vasopressors with midodrine vs. IV vasopressors alone. Results: Among 139 patients, midodrine was associated with increased time to IV vasopressor discontinuation, 5.5 ± 6.5 days vs. 2.4 ± 1.6 days (mean difference 3.1, 95% confidence interval 1.5 to 4.7, P = 0.0003). In patients started on midodrine within 48 hours of stability, time to IV vasopressor discontinuation was similar to the vasopressor alone cohort. Secondary outcomes including ICU and hospital LOS after vasopressor initiation, ICU and in-hospital mortality, and ICU readmission were similar between groups. Twenty patients were discharged from the hospital on midodrine. Incident bradycardia was increased in the midodrine group, but hypertension was similar between groups. Conclusions: Patients in the midodrine group exhibited a longer time to vasopressor discontinuation; however, this difference was only apparent in those with midodrine initiation more than 48 hours after hemodynamic stability in a post-hoc subgroup analysis. These outcomes may be attributed to midodrine being used as salvage therapy.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900251384131"},"PeriodicalIF":1.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Apixaban Lead-In Therapy Duration After Parenteral Anticoagulation on Bleeding in Patients Treated for Venous Thromboembolism. 静脉血栓栓塞患者静脉抗凝后阿哌沙班引入治疗时间对出血的影响。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-01-09 DOI: 10.1177/08971900251313649

Lauren Jackson, Amanda Gillion, Jacob Marler

{"title":"Impact of Apixaban Lead-In Therapy Duration After Parenteral Anticoagulation on Bleeding in Patients Treated for Venous Thromboembolism.","authors":"Lauren Jackson, Amanda Gillion, Jacob Marler","doi":"10.1177/08971900251313649","DOIUrl":"10.1177/08971900251313649","url":null,"abstract":"Background: Venous thromboembolism (VTE) treatment with apixaban uses a higher 10 mg twice daily regimen for 7 days (lead-in therapy). But, in patients with initial parenteral anticoagulation treatment or those with higher bleeding risk, clinicians may not always adhere to the full 7-day lead-in duration. Methods: This retrospective cohort study included adult patients admitted to the Veterans Affairs Health care System from January 2011 to April 2022, who received at least 24 hours of parenteral anticoagulation followed by lead-in apixaban therapy for VTE. The primary outcome evaluated bleeding among patients treated with shortened lead-in apixaban (study group) compared to the standard 7-day duration (control group). Results: Seventy-eight patients were included in the control and 65 in the study group. Most patients were treated for PE (72%) and received initial treatment with enoxaparin (71%). Duration of parenteral anticoagulation was longer in the study group (3.6 days ± 3.2 vs 2.5 days ± 1.9; P < .01), and length of apixaban lead-in therapy was decreased (4.1 days ± 2.2 vs 7 days; P < .01). The primary outcome of bleeding was higher in the study group (18.5% vs 5.1%; P = .02), with no difference in VTE recurrence. P2Y12 and P-gp inhibitor use, and increased creatinine and age were predictors of bleeding. Conclusion and Relevance: Bleeding events were increased in the study group, and patients with bleeding risk factors may not benefit from apixaban 10 mg twice daily. Larger studies are needed where apixaban lead-in therapy is omitted following parenteral anticoagulation in patients with bleeding risk factors.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"430-436"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cangrelor Use for Viabahn Stent Graft Patency as Bridge to Coronary Artery Bypass Graft Surgery. 在冠状动脉搭桥手术中，康瑞洛用于维安支架通畅。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-01-06 DOI: 10.1177/08971900241313275

Jesse Cheng, Rebecca Chui, Jennifer A Mazzoni, Danielle M Pineda, Mauricio J Garrido

引用次数: 0

Enoxaparin-Induced Bullous Hemorrhagic Dermatosis and Enoxaparin Rechallenge: A Case Report. 依诺肝素诱发的大疱性出血性皮肤病和依诺肝素再挑战：病例报告。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-01-05 DOI: 10.1177/08971900241313070

Momoko Tokuo, Stacey Cohen Kaplon

{"title":"Enoxaparin-Induced Bullous Hemorrhagic Dermatosis and Enoxaparin Rechallenge: A Case Report.","authors":"Momoko Tokuo, Stacey Cohen Kaplon","doi":"10.1177/08971900241313070","DOIUrl":"10.1177/08971900241313070","url":null,"abstract":"Purpose: A case of enoxaparin-induced bullous hemorrhagic dermatosis is reported. Summary: A 69-year-old male with past medical history including chronic atrial fibrillation and a re-do aortic valve replacement, anticoagulated on warfarin, received an enoxaparin bridge for a molar extraction. On day 7 after restarting enoxaparin post-procedure at a therapeutic dose of 90 mg every 12 hours, the patient noticed multiple small, dark, raised lesions on his forearm and ankle. The patient denied pain, itchiness, or initiation of new medications other than enoxaparin. The patient had never experienced this side effect in the past, although he had two prior exposures to enoxaparin. A review of the available literature on cutaneous side effects from enoxaparin was performed and it was determined that the patient experienced enoxaparin-induced bullous hemorrhagic dermatosis. There is currently limited guidance on management of this rare side effect and whether enoxaparin rechallenge is safe. As benefit outweighed risk for the patient, the enoxaparin bridge was continued for an additional 3 doses, until the patient completed his supply of enoxaparin at home. Approximately within 1 week after enoxaparin was discontinued, the hemorrhagic bullae disappeared. The patient was re-exposed to enoxaparin 6 months later for a colonoscopy and the side effect did not reoccur. Conclusion: It may be safe to continue enoxaparin while experiencing enoxaparin-induced bullous hemorrhagic dermatosis as the condition is typically self-limiting. This case report shows that re-exposure to enoxaparin may be safe as it may not result in reoccurrence of the side effect.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"452-457"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Significant Publications on Infectious Diseases Pharmacotherapy in 2023. 2023年传染病药物治疗的重要出版物。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-02-06 DOI: 10.1177/08971900251318816

Alex V Stabler, Ricky Huynh-Phan, Khyati Amin, Kevin Lin, Shivani Patel, Noor Zaidan, Stefanie Stramel, Jamie L Thomas

{"title":"Significant Publications on Infectious Diseases Pharmacotherapy in 2023.","authors":"Alex V Stabler, Ricky Huynh-Phan, Khyati Amin, Kevin Lin, Shivani Patel, Noor Zaidan, Stefanie Stramel, Jamie L Thomas","doi":"10.1177/08971900251318816","DOIUrl":"10.1177/08971900251318816","url":null,"abstract":"Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2023. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2023. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. Out of the 31 articles nominated by HIDN members, 22 pertained to general ID pharmacotherapy, and 9 pertained to HIV/AIDS pharmacotherapy. To aid selection of the most notable articles of 2023, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Of the 153 SIDP members who participated in the survey, there were 118 recorded votes for the top 10 general ID pharmacotherapy articles and 55 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: Advances in antimicrobial stewardship and infectious disease states continue to occur. Sustained growth in the publication of ID-related articles over the past year contributed to this review's aim to aid clinicians in remaining current on potentially practice-changing ID pharmacotherapy publications from 2023. This review provides a summary of recently published ID literature, including emphasis on antimicrobial stewardship, appropriate treatment durations, new antimicrobials, and drug-resistant organisms.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"473-485"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective Analysis of Ceftriaxone 1 Gram or 2 Grams for Bacteremia. 头孢曲松1克或2克治疗菌血症的回顾性分析。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-01-11 DOI: 10.1177/08971900241313399

Jae Hee Park, Alan Zhao, Rachel Bain, Bessma Hassani, Christina Tang

{"title":"Retrospective Analysis of Ceftriaxone 1 Gram or 2 Grams for Bacteremia.","authors":"Jae Hee Park, Alan Zhao, Rachel Bain, Bessma Hassani, Christina Tang","doi":"10.1177/08971900241313399","DOIUrl":"10.1177/08971900241313399","url":null,"abstract":"Background: Ceftriaxone is a third-generation cephalosporin commonly used for treating bacteremia caused by gram-positive organisms such as Streptococcus spp. and gram-negative organisms such as Enterobacterales. The typical doses for treating bacteremia are either 1 gram or 2 grams daily. Despite its widespread use, there are limited data on the optimal treatment dose for bacteremia. Methods: This IRB-approved retrospective cohort study evaluated the difference in the clinical failure rate among patients who received 1 gram or 2 grams of ceftriaxone once daily for documented bacteremia. Clinical failure was defined as a composite of the following: antibiotic escalation, escalation to intensive care, and 30-day readmission due to an infectious cause. Adult patients admitted to Long Island Jewish (LIJ) Valley Stream, LIJ Forest Hills, or LIJ Medical Center in 2022 who received ceftriaxone were reviewed for inclusion. Patients were excluded if they received ceftriaxone for endocarditis or meningitis, had a positive blood culture with a ceftriaxone-resistant pathogen, or received ceftriaxone for less than 72 hours. Results: A total of 128 patients were included in this study. Approximately 46.9% of the participants received a 1 gram dose, while 53.2% received a 2 gram dose. 35.4% of patients in the 2 gram group experienced clinical failure compared to 21.7% in the 1 gram group (P = .08, OR 0.51; 95% CI 0.23-1.11). Conclusion: Our findings indicate that the primary outcome of clinical failure did not significantly differ between the 1 gram and 2 gram doses.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"425-429"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic Review of Intrauterine Contraceptive Use and the Development of Toxic Shock Syndrome. 宫内避孕药具使用与中毒性休克综合征发展的系统综述。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-01-08 DOI: 10.1177/08971900241313402

Timothy C Hutcherson, Nicole E Cieri-Hutcherson, Michael A Grosshans, Julia Freemire, Eryn Meegan, Virginia Zu, Elana Tal

{"title":"Systematic Review of Intrauterine Contraceptive Use and the Development of Toxic Shock Syndrome.","authors":"Timothy C Hutcherson, Nicole E Cieri-Hutcherson, Michael A Grosshans, Julia Freemire, Eryn Meegan, Virginia Zu, Elana Tal","doi":"10.1177/08971900241313402","DOIUrl":"10.1177/08971900241313402","url":null,"abstract":"The objective of this systematic review was to characterize the literature regarding the risk factors associated with the development of toxic shock syndrome (TSS) secondary to the use of intrauterine contraceptives (IUCs), as well as patient outcomes. A literature search was conducted spanning origin through December 12, 2022, using Embase and MEDLINE ALL. Primary literature that discussed development of TSS along with the presence of an IUC were included. Extracted data included study and participant demographics, IUC data, and infection data. Reports were evaluated for risk-of-bias using the Joanna Briggs Institute critical appraisal tool for case reports. Thirteen reports met the eligibility criteria, all of which were case reports involving one patient per case who developed TSS following the insertion of an IUC or in the presence of an IUC. The patients included in the review were women aged 23 to 50 years old. Major outcomes reported included time of IUD insertion, bacteria cultured, and antibiotic therapies administered. A minority of the reports (n = 5) provided data related to recent or prior childbirth, miscarriages, or abortions, some of which were proposed to have contributed to development of TSS. Risk-of-bias assessments identified potential concerns in four domains. This systematic review characterized literature pertaining to IUC use and TSS. There may be a low but possible risk of TSS when using an IUC; generalizability is limited given the low quality of available studies. This study was neither registered nor funded.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"463-472"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Retrospective Study Evaluating the Safety and Clinical Impact of High Dose (6.75 grams) Piperacillin-Tazobactam Dosing in Critically Ill Obese Patients for Pneumonia. 评价高剂量（6.75 g）哌拉西林-他唑巴坦治疗重症肥胖肺炎患者的安全性和临床影响的回顾性研究

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-02-03 DOI: 10.1177/08971900251319072

Christina X Tran, Matthew P Crotty, Ronda L Akins

{"title":"A Retrospective Study Evaluating the Safety and Clinical Impact of High Dose (6.75 grams) Piperacillin-Tazobactam Dosing in Critically Ill Obese Patients for Pneumonia.","authors":"Christina X Tran, Matthew P Crotty, Ronda L Akins","doi":"10.1177/08971900251319072","DOIUrl":"10.1177/08971900251319072","url":null,"abstract":"Background: Piperacillin-tazobactam (PTZ) demonstrates time-dependent bactericidal activity, potentially increasing the need for higher dosing in obese and critically ill patients. However, limited information is available on the safety of higher dosing strategies. Objective: To evaluate the safety and clinical impact of high dose 6.75 g IV PTZ for the treatment of pneumonia in critically ill, obese (≥120 kg) patients vs standard dose 4.5 g IV PTZ. Methods: Retrospective, cohort study, multicenter in health-system consisting of four acute-care teaching hospitals. Adult patients weighing at least 120 kg on PTZ for pneumonia in the intensive care unit (ICU) from January 2013 to September 2018 were included. The primary outcome of the study was acute nephrotoxicity defined as initiation of renal replacement therapy and/or serum creatinine increase within 48 hours of last PTZ dose. Secondary outcomes included thrombocytopenia, 14-day all-cause mortality, and ICU length of stay (LOS). Results: One hundred thirty-six patients were included with 52 and 84 in 4.5 g PTZ and 6.75 g PTZ respectively. The rate of acute nephrotoxicity was comparable between cohorts (50% 4.5 g vs 40.5% 6.75 g, P = 0.277). High dose PTZ was not independently associated with acute nephrotoxicity after control for selected confounders. All secondary outcomes were similar. Concomitant vancomycin and calculated supratherapeutic vancomycin area under curve were not independently associated with increased nephrotoxicity. Conclusions: High dose PTZ was not associated with increased acute nephrotoxicity, thrombocytopenia, 14-day all-cause mortality, or ICU LOS. Additionally, more robust trials are needed to fully assess the clinical impact of 6.75 g PTZ dosing for critically ill, obese patients, for pneumonia.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"444-451"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Check-In Protocol: Identifying Medication Issues in Patients with Cancer at Health System Specialty Pharmacy. 早期检查协议：在医疗系统专科药房发现癌症患者的用药问题。

IF 1.1

Journal of pharmacy practice Pub Date : 2025-10-01 Epub Date: 2025-02-04 DOI: 10.1177/08971900251318574

Kayla Ann Phillips, Andrew Wash, Kristin Hutchinson, Katie Jo Cash, Carly Giavatto, Casey Fitzpatrick, Abbey Hunter, Olivia Page, Jessica Mourani, Ana I Lopez-Medina

{"title":"Early Check-In Protocol: Identifying Medication Issues in Patients with Cancer at Health System Specialty Pharmacy.","authors":"Kayla Ann Phillips, Andrew Wash, Kristin Hutchinson, Katie Jo Cash, Carly Giavatto, Casey Fitzpatrick, Abbey Hunter, Olivia Page, Jessica Mourani, Ana I Lopez-Medina","doi":"10.1177/08971900251318574","DOIUrl":"10.1177/08971900251318574","url":null,"abstract":"IntroductionSeveral studies have illustrated value in early patient contact following oral anticancer medication (OAM) initiation, particularly within the first 14 days of therapy, as adverse effects may lead to early discontinuation or poor adherence. Health-system specialty pharmacies (HSSPs) are optimally positioned to adopt this best practice through formalized protocols designed to identify and mitigate medication-related issues.ObjectiveTo outline an HSSP-led early check-in protocol for patients taking OAMs and to describe the subsequent interventions conducted by the HSSP team and their acceptance rate.ResultsHSSPs enacted a protocol in January 2021 requiring oncology pharmacists - to contact patients within 14 days of OAM initiation, aiming to optimize adverse effect management, offer supportive care, address adherence, and provide education. To evaluate the impact of the early check-in protocol, we conducted a retrospective, multicenter, observational study across CPS's health system clients from January 2022 to November 2023. HSSP pharmacists created 1698 interventions for 1184 patients from the early check-in. The cancer types most frequently associated with an intervention were breast (n = 431, 25.4%), gastrointestinal (n = 245, 14.4%), and prostate (n = 206, 12.1%). The most frequent intervention categories were adverse drug reactions (ADRs) (n = 1,548, 91.2%) and adherence (n = 55, 3.2%). Overall, 95.5% of pharmacist recommendations were accepted by patients and/or providers.ConclusionImplementing an early check-in protocol allows HSSP pharmacists to mitigate barriers to OAM adherence. This study emphasizes the importance of early check-in and illustrates the scope of the oncology pharmacist's role by evaluating critically meaningful interventions and quantifying pharmacist recommendations and acceptance rate.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"437-443"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Intravenous Buprenorphine for Acute Pain in Critically Ill Patients in a Medical Intensive Care Unit. 丁丙诺啡静脉注射治疗重症病人急性疼痛的疗效观察

IF 1.1

Journal of pharmacy practice Pub Date : 2025-09-30 DOI: 10.1177/08971900251384153

Kennedi Satterfield, Jessica L Elefritz, Kyle Quirk, Jennica Johns, Sarah Ehrman, Eric M McLaughlin, Brookeanne Magrum

{"title":"Efficacy of Intravenous Buprenorphine for Acute Pain in Critically Ill Patients in a Medical Intensive Care Unit.","authors":"Kennedi Satterfield, Jessica L Elefritz, Kyle Quirk, Jennica Johns, Sarah Ehrman, Eric M McLaughlin, Brookeanne Magrum","doi":"10.1177/08971900251384153","DOIUrl":"https://doi.org/10.1177/08971900251384153","url":null,"abstract":"Background: Buprenorphine is an opioid that has recently gained interest for acute pain management in post-operative patients. It has theoretical advantages due to its unique mechanism and favorable adverse effect profile. Currently, no studies have evaluated intravenous buprenorphine for acute pain management in a critically ill medical patient population.Objective: The objective of this study was to compare the use of intravenous buprenorphine with or without a full agonist IV opioid vs a full agonist IV opioid alone for acute pain in non-ventilated, non-surgical critically ill patients.Methods: A retrospective cohort study was completed of patients who received IV buprenorphine or full-agonist opioids while admitted to the medical intensive care unit at an academic medical center and community hospital.Results: The median DVPRS difference in the buprenorphine group compared to the control group was 5 vs 6. The non-inferiority t-test showed buprenorphine was not significantly non-inferior with mean DVPRS score at day 3 for the buprenorphine group was 5.02 and the control group was 5.07 (P = 0.85). Respiratory depression within 7 days occurred less in the buprenorphine group (20.6% vs 42.9%, P = 0.004). Oversedation occurred less in the buprenorphine group (27% vs 46.8%, P = 0.01. The ICU LOS was longer in the buprenorphine group (8 vs 5 days, P = 0.01). The median daily OME on day 1 was less in the buprenorphine group (29 vs 42.5, P = 0.03).Conclusion: Intravenous buprenorphine may be a comparable alternative to full agonist intravenous opioids for pain control in the medical intensive care unit.","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900251384153"},"PeriodicalIF":1.1,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0